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Abstract
Background: The aim of the present study was to examine symptoms of hypoglycemia, to develop a method to
quantify individual differences in the consistency of symptom reporting, and to investigate which factors affect
these differences.
Methods: Participants recorded their symptoms with every episode of hypoglycemia over a 9–12-month period.
A novel logistic-type latent variable model was developed to quantify the consistency of each individual’s
symptom complex and was used to analyze data from 59 subjects (median age, 57.5 years [range, 22–74 years],
65% male, 77% type 1 diabetes) who had experienced 19 or more hypoglycemic episodes. The association
between the calculated consistency parameter and age, sex, type and duration of diabetes, and C-peptide and
serum angiotensin converting enzyme concentration was examined using a generalized linear model. Analyses
were performed under a Bayesian framework, using Markov chain Monte-Carlo methodology.
Results: Individuals exhibited substantial differences in between-episode consistency of their symptom reports,
with only a small number of individuals exhibiting high levels of consistency. Men were more consistent than
women. No other factors affected consistency in patients with normal hypoglycemia awareness.
Conclusions: By using a novel stochastic model as a quantitative tool to compare the consistency of hypogly-
cemic symptom reporting, much greater intra-individual variability in symptom reporting was identified than
has been recognized previously. This is relevant when instructing patients on identification of hypoglycemic
symptoms and in interpreting symptomatic responses during experimentally induced hypoglycemia.
Introduction
Hypoglycemia is a common side effect of insulin treat-ment that carries a substantial morbidity. Rapid per-
ception of the symptoms of hypoglycemia is essential to
permit early corrective action. Field studies in which adults
with insulin-treated diabetes have reported symptoms expe-
rienced during hypoglycemia have allowed the most common
symptoms to be identified1 and subdivided into autonomic,
neuroglycopenic, and general malaise groups.2
When educating patients about the recognition of hypo-
glycemia, it is important to consider factors that may cause
variation in their symptoms. Hypoglycemic symptoms are
age-specific, in that young children have difficulty recogniz-
ing hypoglycemia3 and often exhibit behavioral changes,4,5
whereas neurological symptoms are prominent in elderly
patients.6 The symptom profile does not differ between type 1
diabetes and insulin-treated type 2 diabetes.7–9 Neither the
causative agent (insulin or tolbutamide)10 nor the patient’s
gender11 influences the nature of the symptoms experienced
during hypoglycemia.
Some hypoglycemia-related symptoms may be more reli-
ably associated with blood glucose levels than others, and a
given symptom is not equally predictive of hypoglycemia in
everybody,12 suggesting a degree of between-subject vari-
ability. It is accepted that each individual’s symptom complex
is idiosyncratic.1 However, an additional important issue is
the degree to which individuals report similar patterns of
hypoglycemia-related symptoms across episodes. The reli-
ability with which these symptoms occur influences the
ability to detect the onset of hypoglycemia.13 The symptoms
reported by children exhibit marked variability between epi-
sodes of hypoglycemia,3 but it is not known whether adults
exhibit similar intra-individual variability.
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The aim of the present study was to examine the symptoms
of hypoglycemia recorded prospectively over a 9–12-month
period by adults with type 1 and type 2 diabetes, to develop a
model for quantifying the consistency of the symptom com-
plex recorded on each occasion by every individual, and to
examine what factors might produce inter-individual differ-
ences in the consistency of symptom reporting.
Subjects and Methods
Data were collected during a 12-month multicenter epide-
miological study that examined the effects of type of diabetes
and treatment modality on the frequency of hypoglycemia in
381 participants, 17–75 years old.14 Subjects were recruited
into five groups: (1) type 2 diabetes treated with a sulfonyl-
urea; (2) type 2 diabetes treated with insulin for <2 years; (3)
type 2 diabetes treated with insulin for >5 years; (4) type 1
diabetes of<5 years in duration; and (5) type 1 diabetes of>15
years in duration.
The clinical diagnosis of type 1 and type 2 diabetes was
corroborated by enzyme-linked immunosorbent assay mea-
surements of glucagon-stimulated C-peptide. The presence of
retinopathy was assessed using digital retinal photography.
Serum angiotensin converting enzyme (considered to be a
putative marker for increased risk of severe hypoglycemia at
the time that the study was designed15–17) and hemoglobin
A1c were measured in a central laboratory. Exclusion criteria
were as follows: hemoglobin A1c >9%, severe diabetes
complications, history of seizures, malignant disease, severe
systemic disease, or pregnancy. The protocol received multi-
center ethics approval. Subjects gave informed consent.
Subjects performed regular capillary glucose monitoring
using a Medisense G glucose meter (Abbott Laboratories,
Abbott Park, IL). All episodes of hypoglycemia were recorded
on standard forms, noting the date, time, duration, symp-
toms, treatment received, and concurrent blood glucose.
Subjects were asked to record all episodes associated with a
capillary glucose <3.0 mmol/L (<54 mg/dL) or any episodes
associated with symptoms typical of hypoglycemia. Al-
though subjects were encouraged to measure blood glucose,
episodes were accepted as valid if typical hypoglycemic
symptoms resolved with carbohydrate, even if no blood
glucose measurement was available. Episodes associated
with glucose levels >4.0 mmol/L were not considered valid.
Symptoms were recorded using a standard list (Table 1). The
state of hypoglycemia awareness was assessed with a vali-
dated scale.18 Each month, subjects returned forms recording
all hypoglycemic episodes with telephone follow-up if no
form was received. As the intensity of hypoglycemic symp-
toms is diminished following antecedent hypoglycemia,19–21
any episode of hypoglycemia occurring within 24 h of a pre-
ceding episode was excluded from further analysis.
Modeling and analysis
In the statistical model developed, individuals report
specific symptoms with a probability that depends on a ran-
dom threshold being crossed. The behavior of thresholds is
modeled through a probability distribution whose degree
of concentration around a central value provides a measure
of an individual’s symptom-reporting consistency. Under a
Bayesian approach, following observation of binary indica-
tors of symptom experience (i.e., whether or not an individual
experiences a given symptom), information on unobserved
latent factors and the variability of the thresholds becomes
available through their posterior distribution, which is ob-
tained using Markov chain Monte-Carlo methodology.22
Bayesian methods and Markov chain Monte-Carlo techniques
are used in the analysis of latent variable models in psychol-
ogy.23,24 Latent variable and threshold models are commonly
used in the behavioral sciences,25 and stochastic methods
have been used in diabetes to model the decision-making
processes that lead to treatment of hypoglycemia.26
Computations were performed using the statistical pack-
age R.27 Markov chain Monte-Carlo techniques were im-
plemented using winBUGS software.28 The lack of previous
similar analyses prevented formal power calculations. A
pragmatic decision was made that participants should have
experienced at least two episodes of hypoglycemia per month
on average. The data were checked for sample bias resulting
from patients with more frequent episodes potentially expe-
riencing lower number of symptoms, but no such association
was found (r¼0.09).
Model for intra-individual consistency
The random threshold determining the probability of an
individual reporting specific symptoms relates to latent var-
iables that govern the intensity of a given symptom on a given
occasion and the individual’s propensity to experience that
symptom. Within our statistical model, assessment of intra-
individual consistency is based on a principle of hierarchical
symptom reporting where order is imposed by both pro-
pensity and intensity. Thus, a symptom is more likely to be
reported if it is intense (e.g., profuse versus mild perspiration)
and if the individual has a strong tendency to experience that
Table 1. List of Symptoms on Patients’ Report Forms
Symptom Description
1 Confusion
2 Sweating
3 Drowsiness
4 Weakness
5 Dizziness
6 Feeling warm
7 Difficulty speaking
8 Pounding heart
9 Impaired concentration
10 Shivering
11 Unsteady
12 Nonspecific awareness
13 Double vision
14 Blurred vision
15 Hunger
16 Thirst
17 Nausea
18 Anxiety
19 Tiredness
20 Tingling
21 Trembling
22 Headache
23 Malaise
24 Irritability
25 Other
26 None
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symptom. This modeling approach can be represented
graphically by regarding each subject’s responses as a JK
matrix of indicator variables (J¼number of symptoms;
K¼number of episodes) (Fig. 1a), where each reported
symptom is represented by a marked cell. Rearranging the
rows according to the frequency with which symptoms are
experienced and the columns according to the number of
symptoms per episode (Fig. 1b), we obtain a representation
where the degree of clustering of marked cells can be regarded
as a measure of consistency.
This is expressed within a parametric framework using a
logistic-type latent variable model. We assume that the
unobservable random thresholds tijk (associated with indi-
vidual i reporting symptom j at episode k) follow a
log-normal(0, r2i ) distribution, under which the probability pijk
of individual i reporting symptom j at episode k is given by
pijk ¼ Pr (sijk  aijbik)¼

log (aijbik)
ri

with i¼ 1, . . . , I, j¼ 1, . . . , J,and k¼ 1, . . . ,Ki, where aij and bik
represent the propensity for symptom j and the intensity of
episode k, respectively, for individual i, and F( ) denotes the
cumulative distribution function of a standard normal vari-
able. Therefore, the model implies that occurrence of symptoms
across and within episodes depends on the relevant propensity
(aij) and also on the underlying episode intensity (bik), which
introduces associations among symptoms through the imposed
hierarchical structure of occurrence. The information available
on the frequency with which symptoms are reported through
all episodes and on the total number of symptoms per episode,
allows estimation of both aij and bik in our model.
The precision parameter r 2i of the threshold distribution
provides a measure of the symptom-reporting consistency of
an individual. Consistent symptom profiles are associated
with low variance of the threshold distribution. For ease of
interpretation r 2i is converted to a consistency parameter
ci¼ 100=(1þ r2i ), which ranges from 0 to 100 with increasing
values corresponding to higher symptom consistency.
Association between consistency
and patient-specific factors
Generalized linear model methodology was used to investi-
gate the effect of the following patient-specific covariates on
consistency: gender, age, diabetes type (1 or 2), duration of di-
abetes, retinopathy, hypoglycemia awareness score (1–7, with
higher scores corresponding to diminishing awareness of hy-
poglycemia), body mass index, stimulated C-peptide, hemo-
globin A1c, and serum angiotensin converting enzyme activity.
For modeling purposes retinopathy was subdivided into no
retinopathy, background retinopathy, and proliferative reti-
nopathy. A generalized linear model with gamma errors (see
Supplementary Appendix; Supplementary Data are available
online at www.liebertonline.com <http://www.liebertonline
.com/dia>) was used to link estimates of the precision pa-
rameter r 2i with the covariates, through the function
log E(r 2i )
 ¼ b0þ bgen ·GENiþ bage ·AGEiþ btype ·TYPEi
þ bdur ·DURiþ bret1 ·RET1iþ bret2 ·RET2i
þ bret3 ·RET3iþ bawar ·AWARi
þ bbmi ·BMIiþ bcpep ·CPEPi
þ bhba ·HBAiþ bace ·ACEi
(where the GEN represents gender, DUR represents duration,
RET1 represents no retinopathy, RET2 represents background
retinopathy, RET3 represents proliferative retinopathy, AWAR
represents awareness of hypoglycemia, BMI represents body
FIG. 1. (a) Example of a JK matrix of indicator variables (J¼number of symptoms; K¼number of episodes) for subject
6010 with symptoms 1–26 listed vertically and hypoglycemic episodes listed horizontally. Each reported symptom is marked
with a square. (b) Rearrangement of the matrix rows and columns so that rows now appear according to the frequency with
which symptoms are experienced and columns according to the number of symptoms per episode (both following a des-
cending order from the top-left corner).
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mass index, CPEP represents C-peptide, HBA represent he-
moglobin A1c, and ACE represents angiotensin converting
enzyme), and the effect of each covariate was assessed using
95% equal-tailed Bayesian intervals of the corresponding b
coefficients.
Results
A total of 3,474 episodes of hypoglycemia from 59 patients
were examined, of which 91% were confirmed by capillary
glucose readings. After exclusion of hypoglycemic episodes
occurring within 24 h of a previous event, 2,699 episodes re-
mained for analysis. Table 2 summarizes the subject charac-
teristics and hypoglycemic episodes within each group. The
most commonly recorded symptoms were weakness, de-
creased concentration, sweating, and hunger (28.7%, 28.2%,
21.8%, and 21.1% of episodes, respectively).
The distribution of the estimated precision parameter er  2i
is skewed, with most subjects having low consistency
(Fig. 2a). Estimates of the converted consistency parametereci¼ 100=(1þ er2i ) have a mean of 50.3 and an SD of 16.7 (Fig.
2b). The main sample quartiles of eci are q0¼ 18.0, q0.25¼ 37.6,
q0.5¼ 50.2, q0.75¼ 62.7, and q1¼ 96.7.
Some subjects in this study merit individual consideration.
Subject 1028 (type 1 diabetes for >15 years) was asymptom-
atic during all of his 45 recorded episodes. He had reported a
hypoglycemia awareness score18 of 7, denoting total loss of
warning symptoms, and had the highest estimated consis-
tency (96.7; 95% Bayesian interval 92.9–98.7). In Bayesian
statistics, the credible or Bayesian interval plays a similar role
to confidence intervals in frequentist statistics. Subject 4003
(type 1 diabetes for >15 years) had the second highest con-
sistency score (75.86; 95% Bayesian interval 60.7–87.6), was
asymptomatic during 74.1% of his reported episodes, and was
the only other subject with an awareness score of 7. Subject
5044 (type 1 diabetes for <5 years) had no symptoms during
51% of her episodes but had a hypoglycemia awareness score
of 2, implying good awareness. Her consistency score was
40.4 (95% Bayesian interval 29.7–51.7). All other subjects were
symptomatic during at least 50% of their reported hypogly-
cemic episodes. The single subject treated with oral agents
was asymptomatic on 36% of episodes, all of which were
confirmed biochemically (blood glucose 3.1–3.5 mmol/L). All
of these subjects were included in the analysis as the presence
or absence of symptoms was considered to form part of the
variability of their symptom profiles.
When the effect of specific covariates on the consistency
measure was examined, gender and hypoglycemia awareness
were the only factors that had a systematic effect. Figure 3a
shows 95% Bayesian intervals for all covariate coefficients.
The mean of the gender coefficient, bgen, was 0.677 (95%
Bayesian interval 1.239, 0.110). This suggests that female
subjects were less consistent than male subjects (gender was
coded as 0¼males and 1¼ females). The mean of the coeffi-
cient of awareness, bawar, was 0.138 (95% interval 0.006, 0.284),
which implies that those with impaired awareness recorded
Table 2. Subject Characteristics and Hypoglycemic Episodes Within Each Group
T2tabs T2Ins< 2 T2Ins> 5 T1Ins< 5 T1Ins> 15 Total
Number in original study
(n¼ 14)
108 89 77 50 57 381
Number of subjects with 19
hypoglycemias
1 4 9 21 24 59
Hypoglycemias per group 25 113 476 1,385 1,475 3,474
Hypoglycemias per group
after hypoglycemias <24 h
of each other excluded
25 104 370 1,095 1,104 2,699
Number of hypoglycemias
per patient
25 (25) 28.5 (20–36) 37 (27–146) 49 (19–210) 44.5 (19–300) 42 (19–300)
Hypoglycemias per patient
after hypoglycemias <24 h
of each other excluded
25 (25) 25 (20–34) 31 (25–105) 44 (19–134) 37 (19–138) 37 (19–135)
Percentage of hypoglycemias
confirmed biochemically
100% 95.2% 89.1% 95.1% 87.8% 91.0%
Asymptomatic episodes
per group (%) after
hypoglycemias <24 h
of each other excluded
36% 0% 9.3% 0.9% 4.5% 11.3%
Number (%) male 1 (100%) 4 (100%) 8 (89%) 14 (67%) 11 (46%) 39 (65%)
Age (years) 51 (51) 65 (60–74) 65 (57–72) 39 (22–70) 58 (34–72) 57.5 (22–74)
Number (%) with impaired
awareness
0 (0%) 0 (0%) 2 (22%) 7 (33%) 13 (54%) 22 (37%)
Body mass index (kg/m2) 23.7 (23.7) 27.8 (26–30.2) 27 (21.9–33) 24 (19.5–29.6) 25.3 (21.6–42.7) 25.0 (19.5–42.7)
C-peptide (nmol/L) 2.22 (2.22) 0.85 (0.27–1.58) 0.24 (0.05–0.21) 0.45 (0.06–0.87) 0.09 (0.05–0.85) 26 (0.05–2.51)
Hemoglobin A1c (%) 7.1 (7.1) 8.3 (7.8–8.8) 7.6 (6.3–8.9) 7.2 (5.6–10.1) 7.8 (6.1–9.7) 7.55 (5.6–10.1)
ACE (IU/L) 20 (20) 13.5 (7–24) 39 (4–71) 34 (18–94) 31.5 (3–98) 32.5 (3–98)
Data are given as median (range) unless otherwise stated.
ACE, angiotensin converting enzyme; T1Ins< 5, type 1 diabetes with <5 years’ duration; T1Ins> 15, type 1 diabetes with >15 years’
duration; T2tabs, type 2 diabetes treated with oral agents; T2Ins< 2, type 2 diabetes treated with insulin for <2 years; T2Ins> 5, type 2
diabetes treated with insulin for >5 years.
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lower variability in their symptoms than those with higher
awareness.
However, if subjects 1028 and 4003 (asymptomatic on 100%
and 74% of episodes, respectively) are excluded from the
analysis, only gender has a significant effect, with females
being less consistent than males (bgen¼0.43 with 95%
Bayesian interval 0.82, 0.03) (Fig. 3b).
Discussion
The present study has demonstrated and quantified
episode-to-episode, intra-individual variability in symptoms
of hypoglycemia reported by adults with diabetes. It has also
found some determinants of inter-individual differences in
this symptom (in)consistency. It is accepted that each indi-
vidual’s hypoglycemia symptom complex is characteristic.
However, the wide range and skewed distribution of the
precision parameter r 2i demonstrate that within-subject
symptom profiles vary substantially between episodes and
that people show marked individual differences with respect
to their consistency of symptom reporting. Conversion of the
precision parameter to the normalized consistency parameter
ci facilitates between- and within-patient comparisons of
consistency estimates, although there is no predefined cutoff
to differentiate consistent and inconsistent individuals.
FIG. 2. Histograms of (a) estimated precision parameter er  2i
and (b) estimated consistency parameter eci¼ 100(1þ er2i ).
FIG. 3. (a) Posterior means (circles) and 95% equal-tailed Bayesian intervals (bars) for standardized coefficients of patient-
specific covariates. bace, serum angiotensin converting enzyme activity; bage, age; bawar, hypoglycemia awareness score; bbmi,
body mass index; bcpep, stimulated C-peptide; bdur, duration of diabetes; bgen, gender; bhba, hemoglobin A1c; bret1, no reti-
nopathy; bret2, background retinopathy; bret3, preproliferative retinopathy; btype, type of diabetes. (b) Analysis repeated after
exclusion of subjects 1028 and 4003.
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The most commonly reported symptoms were weakness,
decreased concentration, sweating, and hunger. These have
previously been demonstrated to be the earliest perceived
symptoms of hypoglycemia29 and those that are most com-
monly13 and accurately12 associated with hypoglycemia.
However, the main aim of this study was not to study pop-
ulation similarities but rather to examine intra-individual
consistency of symptom reporting.
The statistical analyses in the present study raise some im-
portant points for patient education and hypoglycemia re-
search. First, when patients are taught that their hypoglycemic
symptoms are idiosyncratic, they should also be informed that
their symptoms will probably vary between episodes. Re-
inforcing this point may avoid a failure to recognize hypogly-
cemia as a result of symptom variation. Second, it is probably
useful for patients to have an awareness of how consistent their
symptoms are because people who have at least one reliable
symptom of hypoglycemia only detect blood glucose levels
below 3.9 mmol/L on 50% of occasions, whereas individuals
with four or more reliable symptoms recognize similar blood
glucose levels on 75% of occasions.13 Finally, previous studies
have relied on very few snapshots of the hypoglycemic symp-
tom profile, either recorded during experimental hypoglyce-
mia10,11,30,31 or documented retrospectively by patients in what
was thought to represent their ‘‘typical’’ symptom profile.2,6–8,32
The findings of the present study challenge the validity of the
latter approach for the purpose of advising individual patients,
as the degree of between-episode variability is much greater
than has previously been appreciated.
Of the factors examined, only female gender increased
symptom variability in a systematic way. Although impaired
awareness was associated with increased symptom consis-
tency in the initial analysis, this effect was no longer observed
once the two individuals with awareness scores of 7 were
excluded. One of the limitations of this analysis is that it
cannot distinguish between a completely consistent person
with full symptom awareness and a consistently asymptom-
atic individual. However, for individuals with a combination
of symptomatic and asymptomatic episodes, the presence or
absence of symptoms contributes to the consistency of their
symptom profile, and it was thought important not to exclude
asymptomatic episodes completely.
It was surprising that the subject treated with oral agents
was asymptomatic during 36% of episodes, despite recording
a normal hypoglycemia awareness score.1 All his episodes
were confirmed with glucose readings. In the United King-
dom, patients treated with oral agents are not routinely asked
to check capillary glucose levels, so he had probably not re-
alized that his awareness was impaired prior to participation
in this study.
The relationship between consistency of symptom report-
ing and gender has not been reported previously. Symptoms
of hypoglycemia develop at similar blood glucose thresholds
in men and women with type 1 diabetes,33 but the magnitude
of the counterregulatory response is lower in women,34 which
may influence the intensity of the symptomatic response.
Female counterregulatory responses are less affected by an-
tecedent hypoglycemia and exercise than responses in men.35
It could be hypothesized that the gender differences in this
study relate to under-reporting by females as a result of lower
symptom intensity, but it is not possible to confirm this as
subjects were not asked to note symptom intensity.
It is possible that other factors, such as the activities en-
gaging the individual at the time of the episode, may have an
effect on symptom consistency, but it would be logisti-
cally difficult to study these in greater detail. Earlier work
has classified hypoglycemic symptoms in physiological
terms.2,4,6–8 Appropriate grouping of symptoms may be able
to account for additional sources of between-group variation
for an individual patient in the model, thus giving scope
for including relevant effects for symptom groups in future
analyses.
Not all hypoglycemic episodes in this study were con-
firmed biochemically. However, the presence of typical
symptoms that resolve with ingestion of carbohydrate is
conventionally taken as evidence of hypoglycemia. Insistence
on biochemical corroboration would have further restricted
the number of episodes available for analysis and most epi-
sodes (91%) were confirmed.
In subjects with normal awareness, it would be interesting
to stratify episodes according to blood glucose level to in-
vestigate whether this had an effect on symptom reporting.
However, this was not possible in the present study for sev-
eral reasons. Although a fall in blood glucose in a adult
without diabetes triggers the secretion of counterregulatory
hormones and the onset of cognitive and symptomatic
changes at reproducible blood glucose thresholds33,36 within a
defined hierarchy,37 these thresholds become altered in dia-
betes, and the same blood glucose level may affect individuals
with diabetes in different ways. Second, data from field
studies can never be as controlled as data generated in a
laboratory. Confirmation of hypoglycemia may have oc-
curred several minutes before or after rescue carbohydrate
was administered. Thus, the blood glucose measurement may
not have coincided exactly with the blood glucose nadir or the
peak of symptom intensity. Finally, blood glucose meters are
less accurate in the hypoglycemic range, and it would not
have been possible to confirm these readings with venous
samples outside the confines of a tightly regulated laboratory
study. However, there is the potential to examine this ques-
tion in a follow-up study.
The study has several strengths, including its size (2,699
episodes of hypoglycemia), its prospective design, and its du-
ration. Although some previous studies have collected symp-
toms prospectively,12,38,39 they have not attempted to compare
symptoms between episodes. Furthermore, prospective field
data could be regarded as more generalizable than hypogly-
cemia data collected under laboratory conditions.
The present study demonstrates that intra-individual
between-episode symptom variability is much greater than
has been previously appreciated and that there are marked
individual differences in this consistency. Caution should be
exercised when interpreting patients’ retrospective recall of
what they regard to be their ‘‘typical’’ hypoglycemic symp-
toms. Female gender was the only factor found to have a
systematic association with increased variability of the
symptom complex. Given this observed variability, clinicians
should advise patients against being too dogmatic in their
perception of what constitutes their cardinal hypoglycemic
symptoms, as these may vary considerably between episodes.
This variability should also be considered when interpreting
hypoglycemic symptom responses under different experi-
mental conditions or when comparing different therapeutic
interventions.
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